See more : Stratus Properties Inc. (STRS) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- Volato Group, Inc. (SOAR) Income Statement Analysis – Financial Results
- Tainwala Chemicals and Plastics (India) Limited (TAINWALCHM.BO) Income Statement Analysis – Financial Results
- Shandong Sunpaper Co., Ltd. (002078.SZ) Income Statement Analysis – Financial Results
- Mike the Pike Productions, Inc. (MIKP) Income Statement Analysis – Financial Results
- CELM,Inc. (7367.T) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
Corgenix Reports Record Quarterly Sales Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased substantially, both for the...
Corgenix to Host Conference Call to Discuss Third Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, May 14, 2012, at 4:00 p.m. EDT to discuss the Company’s financial and operating performance for its...
Corgenix Automated Hyaluronic Acid (HA) Test Kit Now CE Marked
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today its second generation Hyaluronic Acid (HA) Immmunoturbidimetric Test Kit for use on automated chemistry analyzers has received CE marking for commercialization in...
Corgenix Reports Second Quarter Fiscal 2012 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased both for the quarter...
Corgenix to Host Conference Call to Discuss Second Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Tuesday, February 14, 2012, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its...
Corgenix Announces New Automated Hyaluronic Acid (HA) Test Kit at MEDICA 2011
DENVER & DUSSELDORF, GERMANY--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, announced today the launch of its new Hyaluronic Acid (HA) Immmunoturbidimetric Test Kit for use on automated chemistry analyzers. The announcement...
Corgenix Reports First Quarter Fiscal 2012 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today filed its fiscal quarter Form 10-Q and reported financial results. The report disclosed that the company’s operating results have advanced for the quarter...
Corgenix to Host Conference Call to Discuss First Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, November 14, 2011, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its...
Zack’s Investment Research Initiates Coverage on Corgenix Medical Corporation with “Outperform” Rating
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that Zacks Investment Research has initiated coverage of the company. The following summarizes the Outlook and the entire report on Corgenix will...
Corgenix Partners with AXA Diagnostics on SkyLAB 752™ Automated Testing Platform
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCQB: CONX), a worldwide developer and marketer of diagnostic test kits, has entered into a U.S. distribution agreement with strategic partner AXA Diagnostics Srl of Pomezia, Italy. Under terms of the agreement, Corgenix will market AXA...
Source: https://incomestatements.info
Category: Stock Reports